In the face of the current time-sensitive COVID-19 pandemic, the limited capacity of healthcare systems resulted in an emerging need to develop newer methods to control the spread of the pandemic. Artificial Intelligence (AI), and Machine Learning (ML) have a vast potential to exponentially optimize health care research. The use of AI-driven tools in LMIC can help in eradicating health inequalities and decrease the burden on health systems. The literature search for this Scoping review was conducted through the PubMed database using keywords: COVID-19, Artificial Intelligence (AI), Machine Learning (ML), and Low Middle-Income Countries (LMIC). Forty-three articles were identified and screened for eligibility and 13 were included in the final review. All the items of this Scoping review are reported using guidelines for PRISMA extension for scoping reviews (PRISMA-ScR). Results were synthesized and reported under 4 themes. (a) The need of AI during this pandemic: AI can assist to increase the speed and accuracy of identification of cases and through data mining to deal with the health crisis efficiently, (b) Utility of AI in COVID-19 screening, contact tracing, and diagnosis: Efficacy for virus detection can a be increased by deploying the smart city data network using terminal tracking system along-with prediction of future outbreaks, (c) Use of AI in COVID-19 patient monitoring and drug development: A Deep learning system provides valuable information regarding protein structures associated with COVID-19 which could be utilized for vaccine formulation, and (d) AI beyond COVID-19 and opportunities for Low-Middle Income Countries (LMIC): There is a lack of financial, material, and human resources in LMIC, AI can minimize the workload on human labor and help in analyzing vast medical data, potentiating predictive and preventive healthcare. AI-based tools can be a game-changer for diagnosis, treatment, and management of COVID-19 patients with the potential to reshape the future of healthcare in LMIC.
21 August 2021 in International Journal of Medical Informatics
Radiomics is a mathematical approach to medical images to extract quantitative features generating a “radiomics signature.” The radiomics workflow involves image acquisition and pre-processing, region of interest segmentation, feature extraction, and then model training and validation. It has generated promising results, however, clinical implementation for early detection remains a challenge. Pancreatic ductal adenocarcinoma (PDAC), the most common pancreatic cancer, has a highly aggressive nature with an aggregated 5-year survival rate of only 13%. Early detection of PDAC provides timely surgical intervention, hoping for improved survival rates. Radiomics has been applied to the detection of PDAC; however, its sensitivity to variations in image acquisition parameters has posed significant challenges, limiting the development of robust and generalizable models. This review explores the current landscape of radiomics for the early detection of PDAC, highlighting key challenges within the radiomics workflow and barriers to its progression from a proof-of-concept into clinical practice.
Primary hepatic angiosarcoma (PHA) is a rare and aggressive malignancy, accounting for roughly 2% of primary hepatic cancers. It is characterized by rapid progression and nonspecific clinical symptoms, making early diagnosis challenging. This case report describes a 59-year-old male who initially presented with right upper quadrant (RUQ) pain, dizziness, and presyncope, with initial imaging findings suggesting hemoperitoneum secondary to hepatic arteriovenous malformations (AVM). A comprehensive diagnostic approach, including computed tomography (CT) angiography, magnetic resonance imaging (MRI), and surgical biopsy, ultimately confirmed PHA. This case underscores the difficulty in diagnosing PHA due to its varied imaging presentations and highlights the need for improved diagnostic strategies and early detection.
Primary myelofibrosis (PMF) is a rare and progressive bone marrow cancer characterized by fibrosis, abnormal megakaryocyte proliferation, and impaired blood cell production. We present a case of a 65-year-old male diagnosed with accelerated PMF and periportal extramedullary hematopoiesis. Despite a history of stable myelofibrosis, the patient developed progressive hepatosplenomegaly and persistent anemia. Imaging studies, including MRI and CT scans, revealed periportal masses concerning for malignant infiltrative process. Subsequent biopsies confirmed the diagnosis of a sclerosing extramedullary hematopoietic tumor. Treatment included JAK2 inhibitor therapy, blood transfusions, and an eventual bone marrow transplant. This case highlights the complexities in diagnosing and managing PMF, particularly with rare complications like periportal extramedullary hematopoiesis, and underscores the importance of integrating radiological and pathological findings for optimal management.